WE PERCEIVE. WE PREPARE. WE PROTECT.

Continuing 25 years of protecting against public health threats

Whether it’s increasing access to NARCAN® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver vaccines and therapeutics, Emergent’s focus remains on protecting communities and addressing the evolving landscape of global health challenges.

LEARN MORE

Joseph C. Papa

Capabilities

We are a leader in providing solutions that address public health threats and bring lifesaving, life-extending products to market.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.

  • Bioservices

    Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.

Woman in Lab

At Emergent, our mission is to protect and enhance life.

View our 2023 Annual Report

Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith

GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opioid emergency awareness public education campaign to prepare people across the country to help save a life with the ‘Lay, Spray, Stay’ method.

Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024

GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance.

Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada

WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN® Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN® Nasal Spray the only 4 mg, intranasal naloxone spray in Canada with this extended expiration date. The Health Canada notification to extend NARCAN® Nasal Spray’s shelf-life was completed on February 2, 2024.

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.